Low-dose oral isotretinoin for moderate to severe seborrhea and seborrheic dermatitis: a randomized comparative trial

Author(s)

Leao Kamamoto, Cristhine de Souza ; Sanudo, Adriana ; Hassun, Karime M. ; Bagatin, Edileia

• Document type: Journal article
• Source: INTERNATIONAL JOURNAL OF DERMATOLOGY; v. 56, n. 1, p. 80-85, JAN 2017.
• Web of Science Citations: 6

Abstract

BackgroundThe efficacy of low-dose oral isotretinoin in the treatment of seborrhea and seborrheic dermatitis has been poorly investigated in randomized studies. ObjectivesThis study was designed to determine the efficacy and safety of low-dose oral isotretinoin in the treatment of moderate to severe seborrhea and seborrheic dermatitis on the scalp and/or face. MethodsA randomized, comparative clinical trial, using two groups, was conducted over 6 months. Patients in Group ISO were treated with isotretinoin 10 mg every other day. In Group X, patients received antiseborrheic topical treatment. Patient opinion, investigator assessment, scalp pruritus, sebum production, and quality of life (QoL) comprised the efficacy outcomes. ResultsThe intention-to-treat population comprised a total of 45 patients with mean standard deviation ages of 28.7 +/- 5.8 years in Group ISO and 29.8 +/- 6.5 years in Group X. The rate of sebum production significantly decreased in Group ISO. Patient opinion, investigator, and QoL assessments improved in both groups. ConclusionsLow-dose oral isotretinoin can be a therapeutic modality for moderate to severe seborrhea and seborrheic dermatitis. (AU)

• FAPESP's process: 10/51049-1 - Clinical, laboratorial and quality of life trial to evaluate the efficacy and safety of low-dose oral isotretinoin for seborrhea
• Grantee: Ediléia Bagatin
• Support Opportunities: Regular Research Grants